Nouvelle présentation Investisseur sur le site

https://pharnext-website.cdn.prismic.io/pharnext-website/c8016d6f-b988-493a-95b4-576e4da59e93_2023.01.16_Pharnext_Corporate_Presentation.pdf

Des infos fraiches

Significant portion of core target patient population already located

- ~26,000 CMT1A patients located in the US and EU5 through market research, claims data analysis, field

activities and PAGs

- Several patient registries available: GRIN, INC, CMT-Net, etc.

- Plans to go beyond prior launch with MSLs and sponsored Dx campaign

▪ Primary target treating physicians identified (cover >80% of CMT patients)

- Neurologists (NMD specialists), GPs, podiatrists, PTs

▪ Strong relationships developed with key stakeholders

▪ Patient advocacy groups

▪ KOLs and scientific societies

▪ Generation of pharmacoeconomic data prior to launch

▪ CMT&Me: digital lifestyle study sponsored by Pharnext (>2,600 patients enrolled)

Continual assessment of commercial partnership options for various geographies, including US, EU,

Japan and ROW; China commercialization rights are licensed to GeneNet, a JV formed by Pharnext & Tasly